The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy

MLA

Darran P. O’Connor, et al. “The Clinical Impact of Early Immunological Responses in Human HER2-Positive Breast Cancers on Responsiveness to Trastuzumab-Based Therapy.” Journal of Clinical Oncology, vol. 34, May 2016, p. 587. EBSCOhost, https://doi.org/10.1200/jco.2016.34.15_suppl.587.

APA

Darran P. O’Connor, Ailis Fagan, Arnold D.K. Hill, Colm Power, Malgorzata Milewska, William M. Gallagher, Ausra Teiserkiene, Leonie S. Young, Janice M. Walshe, Sinead Toomey, Norma O’Donovan, Alex J Eustace, Deirdre Duke, Elaine W. Kay, Joanna Fay, John Crown, M. John Kennedy, Bryan T. Hennessy, & Niamh Hambly. (2016). The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy. Journal of Clinical Oncology, 34, 587. https://doi.org/10.1200/jco.2016.34.15_suppl.587

Chicago

Darran P. O’Connor, Ailis Fagan, Arnold D.K. Hill, Colm Power, Malgorzata Milewska, William M. Gallagher, Ausra Teiserkiene, et al. 2016. “The Clinical Impact of Early Immunological Responses in Human HER2-Positive Breast Cancers on Responsiveness to Trastuzumab-Based Therapy.” Journal of Clinical Oncology 34 (May): 587. doi:10.1200/jco.2016.34.15_suppl.587.